Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elite barely has any debt and ST liabilities are easily covered by ST receivables.
Who cares if people are looking, the timing has to be right? You can only negotiate a certain multiple if the metrics tell that story. This isn’t magic.
If we start seeing Vyvanse and generic Oxy get approval and launched ok, now we have some momentum and negotiating power that we are bigger than a one trick pony (which we will be).
It would be asinine to entertain any offer now when the value increases significantly upon FDA approval, launch and more with market acceptance.
Could be both. Usually when you’re in the Private Equity space you work with an investment banker that targets certain suitors once the owner wants to unload for various reasons. Then pool gets narrowed down to gold card status and then to a select few.
Sometimes it could be a competitor lurking. In our situation, we will likely work with an investment banking group to help with the due diligence process and facilitate a sale regardless if we are pursued aggressively or we seek it out on our own.
Will be interesting to see how all this unfolds and at what multiple. I’d like to think we have too much in the pipeline to even think about this route for now.
If a company pursues us now, an acquisition would get rejected by shareholders/Nasrat until we can further monetize pipeline. Really looking forward to what’s after our last CNS launch other than upcoming known launches.
It’s never mandatory, but you hire 3rd party consultants to evaluate. Usually you only hear if it would be favorable or unfavorable, not a specific share price.
Why? When there’s still so much more to come. We may not see another until the buyout share price is communicated.
In the end, I won’t mind. :)
Disregard - thought you meant product lines from operations standpoint. We’ve also been spending R&D for quite some time without any BE studies. Expecting some to be released soon.
Why would that be R&D? That’s more fixed assets that would hit P&L via depreciation one the asset’s life. What am I missing?
Lol less than a trillion. :)
We saw a slip after last Q in share price, which I primarily attribute to a similar margin rate decline. If this is a meh earnings call I wouldn’t be surprised if share price stays flat/falls based on this. You can argue all you want, but you find me a company that has deteriorating margins and spun it into a positive story for investors and I’ll happily change my view. Hint: you won’t find it.
However, I’ve been here a long time and am not going anywhere as the incremental intrinsic value continues to build and the company continues to launch.
I want to hear about the pipeline and new facility more than anything. No BE studies revealed yet and yet R&D spend continues to increase at a very good clip.
Doesn’t look like methotrexate launched yet. Lots of news on horizon before end of calendar year.
I’ll be diving into the Q shortly. Couple of interesting things popped looking at financials.
Margin rate pressure is always viewed negatively. I have never ever seen margin rate deterioration viewed positively. Ever.
I understand your point, but that’s a stretch from a financial view.
“lower product margins required to increase and maintain the level of sales.“
It means they can adjust pricing, but it means there are competitive pressures to decrease the price leading to lower rev and profitability.
Not sure I’d interpret that entirely as good news.
Bring me down a bit to $19.3. :)
FYI - I’ve sent you my guess twice.
Believe it or not, Schwab mobile is little glitchy, but still works for me this morning.
Glad you mentioned that. I wanted to dive into inventory mix vs revenues over past several quarters.
Boards are less and less independent these days. It’s a I’ll scratch your back if you scratch mine type situation, regardless of size of company. They (and Nasrat) have a fiduciary duty to shareholders, but that is a costly and big gray area to try and prove out in courts.
Majority of my ownership are in Roth IRAs…
Interesting and very realistic thought. We could always use some fresh perspective, but this will just bring out a few crazies as well. There certainly is no shortage of them today.
*the upside
I agree. Your guess was just barely north of mine. I’d happily take three upside as well. We also know using the old facility they were running out of storage capacity. I’d be pleasantly surprised if they hit over $20M for the Q.
Capacity of 3-4x will come before the revenues flow. Looking forward to seeing Methotrexate launched soon and repurchased ANDAs launched by end of year.
I’m hoping we have some movement on dopamine agonist and BE studies. Haven’t heard about any R&D progress all year. I believe the target was to have 2 filings this year. Not sure that is realistic without any positive BE studies at this point.
Nice to see a little more volume for the pre-earnings play. I’m not expecting this next cc to be anything huge. Just updates on continued progress. By next cc in Nov,
We will have received a response from FDA on Vyvanse. I’m expecting a minor CRL with approval early 2025 and launch mid-year. Lots of launches back half of 2024 to drive top line.
Nice floor at 0.1875 to end the week
Might want to put down the magic 8 ball.
$19.45M. Nice increase in inv, but expecting it to be softer than expectations with no commentary on Q1 revs after the entire Q was in hand. I’ll happily take more upside.
Put me down for $19.45M
14th after close should be correct, being 45 days after quarter end.
If anything new is disclosed you trip a Reg-FD requirement to disclose the same info for all. However, public companies covered by analysts have individual calls with each investment firm post-earnings call. These conversations aren’t black/white. Whole lot of gray as the firms try to get clarification with Q&A broader earnings call didn’t provide. Can go deeper into numbers for modeling purposes.
Price today would be very different than price I anticipate in 2 years for Elite.
None of us have line of sight to Mikah other than % profit splits with Elite. Who knows what else Nasrat has cooking over there.
I could see some hesitation from a buyer from acquiring, but everything can be negotiated. I personally wouldn’t want Mikah involved from that angle as I’d want Nasrat to be 100% focused from Elite’s standpoint, but that’s out of our control.
A buyout would happen regardless, just means that Nasrat negotiated for himself and Elite in a buyout situation if Mikah were to still be involved.
We should get the PR this week about subsequent week’s Q1 earnings release and cc. Earnings due on 14th and cc should be morning of 15th.
Looking for a nice update - methotrexate launch, pipeline movement, new facility should be close to or near final commercialization approval, generic oxy, repurchased opioids, methadone, codeine with APAP launch, etc. Few months away from initial FDA response on generic Vyvanse. So much going on in back half of year.
Are they going to start giving their drugs out for free now? You win the most ridiculous comment of the day.
Zack’s didn’t have a price target in their research report. They left it blank.
I put Pharma Sleuth on ignore long ago. Only so much I can take.
Disappointed? Unless you are disappointed with success perhaps. Nothing but solid potential here. The going concern risks of yesteryear are but a distant memory. Back half of year will be full of launches, continued financial strengthening, reinvesting and pipeline growth.
Would love to hear about Dexcel or others from international opportunity standpoint, but we have so much domestic opportunity to tackle, that would simply be icing on the cake.
For years, investors had to deal with the execution at a snail’s pace where the company was barely limping along. We are finally, finally in full execution mode here. It’s been a long time coming. Enjoy the ride.
No target price made.
Those market sizes are publicly known for each of the drugs we acquired and/or filed.
Huge spread between b/a as volume wanes. I’d expect volume to pick up a little more leading into the cc even if no news is released.